Janssen Reports Post-Hoc Analysis of Tremfya (guselkumab) in P-III (DISCOVER-2) Study for Active Psoriatic Arthritis
Shots:
- The P-III (DISCOVER-2) study evaluating Tremfya (SC) vs PBO in 739 biologic-naïve patients with active PsA
- The results showed clinical improvements in most measures, improvements in overall & physical HRQoL from 1-2yrs. in early clinical responders over patients without early response while long-term HRQoL benefits were also observed in non-early responders treated with Tremfya
- Additionally, a significant benefit for reducing fatigue as early as 8wk. was observed over PBO. In a separate post-hoc analysis, improvements in fatigue @1yr. resulted in greater proportions of patients achieving normative FACIT-F levels, improvement of ≥2 points in FACIT-F by 8wk. that predicted an improvement of ≥4 points @100wk.
Ref: Janssen | Image: Janssen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
